Form 8-K - Current report:
SEC Accession No. 0001326190-26-000013
Filing Date
2026-03-05
Accepted
2026-03-05 07:08:14
Documents
13
Period of Report
2026-03-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20260305x8k.htm   iXBRL 8-K 43416
2 EX-99.1 alt-20260305xex99d1.htm EX-99.1 180225
3 GRAPHIC alt-20260305xex99d1002.jpg GRAPHIC 7092
  Complete submission text file 0001326190-26-000013.txt   385915

Data Files

Seq Description Document Type Size
4 EX-101.SCH alt-20260305.xsd EX-101.SCH 24994
15 EXTRACTED XBRL INSTANCE DOCUMENT alt-20260305x8k_htm.xml XML 4820
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 26724166
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)